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Electrophysiology results at conclusion of treatment
Renal cell carcinoma (RCC) is the 6th most common
cancer in the U.S., and nearly half of these patients
develop cardiovascular (CV) side-effects from the
gold-standard therapy—tyrosine kinase inhibitors
(TKIs)1-3. Most patients with cancer now die from CV
disease rather than from cancer itself. Hence it is
imperative to explore the mechanisms by which these
life-saving drugs induce heart failure (HF) in order to
develop strategies to mitigate these effects and
sustain cancer treatment for as long as possible.
Pazopanib is a TKI that inhibits vascular endothelial
growth factor receptors (VEGFRs) and it is approved
by the FDA for the treatment of various cancers
including RCC. The clinical use of pazopanib and
other TKIs is strongly limited by their association with
serious CV side effects. Although little is known about
the mechanism of TKI-induced cardiotoxicity, this drug
causes serious CV effects in 50% of treated patients,
including HTN, HF and myocardial ischemia1-3. We are
currently using the murine model to study the effects
of pazopanib in-vivo.
We have created a structural heart disease model in
mice which display early signs of HF similar to
humans. These mice (βIIS-cKO mice) lack cardiac βII-
spectrin, a cytoskeletal protein that is important for the
structural integrity of the cell. Our previous work has
shown that these mice have arrhythmias, spontaneous
Ca2+ release and abnormal expression/localization of
cardiac membrane proteins4. Wild type (WT) mice with
induced HF show downregulation of βII-spectrin
accompanied by breakdown peptides which may
serve as early blood and urine markers for HF.
These results in mice resemble the hypertensive CV effects of TKIs seen in humans and
warrant further investigation. We plan to repeat this experiment using various susceptible
mouse populations (Fig. 4) in order to observe advanced HF phenotypes. Transverse aortic
constriction (TAC) will be used to induce HF. TAC mice and βIIS-cKO mice will be treated with
pazopanib under the same dosing conditions used in this experiment. A portion of these mice
will be treated with a renin-angiotensin-aldosterone antagonist (RAAA). Mass spectrometry will
be used to identify βII-spectrin breakdown peptides in blood and urine from mice treated with
pazopanib. This experimental design will allow us to:
• Unravel the cardiotoxic molecular mechanism of TKIs within the cell
• Assess the role of the renin-angiotensin-aldosterone (RAA) system in sustained HTN
• Observe the downstream effects of TKI treatment on βII-spectrin
• Test a potential new biomarker for early signs of TKI-induced cardiotoxicity
Mice
8 Week old black male WT mice were orally dosed with 30 mg/kg
of pazopanib twice daily for 42 days. Transgenic mice (βIIS-cKO
mice) which lack cardiac βII-spectrin were observed at baseline.
Mouse Measurements
Organ weights and tibia length from mice were measured
immediately after removal at the conclusion of the experiment.
Echocardiography (Echo)
The Small Animal Imaging Core’s Vevo2100 echo machine was
used to obtain images once per week.
Surface Electrocardiograms (ECG)
Surface ECG’s were obtained once per week.
Immunoblots
Mouse whole heart lysates were electrophoresed and tested for
several antibodies of interest.
Blood Pressure
The CODA system was used to gather non-invasive blood
pressure readings once per week.
Electrophysiology
Ventricular cardiomyocytes were isolated from mice and used for
electrophysiology testing in vitro.
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Figure 1. Mean arterial pressure over time of control group
(black) compared to mice treated with pazopanib (red). A two-way
ANOVA showed a significant increase (p<0.05) in mean arterial
pressure due to drug treatment but not due to time (n=7). * indicates
statistical significance. Error bars represent + standard error of mean.
Hz/TREATMENT APD50 +/- SE APD75 +/- SE APD90 +/- SE
0.5 WT 2.08 +/- 0.13 5.29 +/- 0.63 12.20 +/- 2.22
0.5 DRUG 3.33 +/- 0.60 8.26 +/- 1.32 16.14 +/- 2.12
1.0 WT 1.92 +/- 0.15 4.77 +/- 0.58 10.11 +/- 1.31
1.0 DRUG 3.13 +/- 0.58 7.74 +/- 1.27 15.20 +/- 1.96
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Figure 2. Pazopanib treatment causes precursors to arrhythmias.
Average action potential duration (APD) 50, 75 and 90 of myocytes
from treated mice (red) was significantly elevated compared to control
myocytes (black). 2/6 myocytes from treated mice developed delayed
afterdepolarizations (DADs) while these were not observed in 5
control myocytes (n=2).
Figure 3. Immunoblots from WT whole heart
tissue at the conclusion of pazopanib treatment
(A-C) and from βIIS-cKO whole heart tissue at
baseline (D). There were no significant changes in
protein expression levels of βII-spectrin, VEGFR-2, or
troponin-I (a biomarker for necrosis and apoptosis)
(A-C). βIIS-cKO mice have significantly decreased
expression of VEGFR-2 at baseline compared to
control mice (D).
βII-spectrin
Troponin-I
Control     Treatment
Control    Treatment
Control   Treatment
150
37
250
150
25
150
Echoes did not show structural changes in the hearts
of mice treated with pazopanib (n=7). ECGs did not
show visible arrhythmias in treated mice (n=7). There
were no significant changes in mouse measurements
(weight, heart weight, kidney weight, brain weight and
tibia length) due to treatment (n=7).
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Figure 5. The cardiotoxicity of pazopanib and other TKIs may be linked to βII-spectrin
and the RAA system. A shows the normal role of the VEGF signaling pathway in
angiogenesis and vascular development (green). B shows the mechanism for pazopanib-
induced disruption of angiogenesis and cardiac homeostasis (red). mTOR, mechanistic target
of rapamycin; CaMKII, Ca2+/calmodulin-dependent protein kinase 2; PLB, phospholamban;
RYR2, ryanodine receptor 2; NCX, Na+/Ca2+ exchanger.
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Figure 4. Experimental treatment
design. Each WT group will have a
companion group that undergoes TAC
for a total of six WT groups. Each TAC
animal will be paired with a sham-
operated animal for comparison.
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